Clinical Trial Update: Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL) [Phase 2]

View source ↗

Summary

Phase 2 trial of crizanlizumab for retinal vasculopathy with cerebral leukoencephalopathy (RVCL) has completed and results are posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinal Vasculopathy with Cerebral Leukoencephalopathy

Drugs mentioned

• Adakveo (crizanlizumab) (Crizanlizumab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy | Phase 2 | Status: COMPLETED | Results posted: 2026-04-23